Estimated reading time: 3 minutes
Financial Performance
Eli Lilly delivered a strong Q2 2025, with 38% revenue growth driven by Mounjaro and Zepbound, though disappointing orforglipron trial results weighed on sentiment.
[](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2025-financial-results-and-raises)[](https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html)| Metric | Value | Consensus Estimate | Year-Over-Year Change |
|---|---|---|---|
| Revenue | $15.56 billion | $14.71 billion | +38% |
| EPS (Adjusted) | $6.31 | $5.57 | +92% (from $3.28) |
| Gross Margin | 85.0% | N/A | +3.0 points |
| Zepbound Revenue | $3.38 billion | $3.06 billion | +172% |
Product Performance: Mounjaro and Zepbound drove growth, with Mounjaro achieving market leadership in U.S. type 2 diabetes prescriptions. Orforglipron’s trial showed 12% weight loss (27.3 lbs) at the highest dose, below Wall Street expectations, with high nausea rates.
[](https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html)Market Reaction
Stock Movement: Shares fell up to 12% in pre-market trading on August 7, 2025, due to orforglipron’s disappointing results, despite the earnings beat.
[](https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html)Analyst Sentiment: Analysts remain bullish on Lilly’s GLP-1 portfolio but lowered expectations for orforglipron due to competitive concerns. Price targets range from $883 to $1,190, implying 15–55% upside.
[](https://www.cnbc.com/2025/08/06/eli-lilly-earnings-are-coming-thursday-what-top-analysts-expect.html)Operational Insights
Pipeline Challenges: Orforglipron’s lower efficacy and high side effects compared to competitors like Novo Nordisk’s oral semaglutide could limit its market potential.
[](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2025-financial-results-and-raises)Market Leadership: Lilly gained market share in the $200 billion incretin market, with plans to expand manufacturing capacity by 1.6x in H1 2025.
[](https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html)R&D Focus: Investments in oncology, immunology, and Alzheimer’s aim to diversify beyond GLP-1 drugs. Recent acquisitions of SiteOne and Verve Therapeutics enhance pain and cardiovascular portfolios.
[](https://www.benzinga.com/markets/earnings/25/08/46974422/eli-lilly-q2-2025-earnings-orforglipron-data-transcript)Guidance
FY 2025 Outlook: Lilly raised its revenue guidance to $60–$62 billion (from $58–$61 billion) and adjusted EPS to $21.75–$23 (from $20.78–$22.28), reflecting strong GLP-1 demand.
[](https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html)Risks
Competitive Pressure: Novo Nordisk and others could erode GLP-1 market share.
Regulatory Risks: Orforglipron’s high dropout rate may delay approval.
Tariff Concerns: Potential U.S. tariffs on imported pharmaceuticals could impact costs, though not factored into guidance.
[](https://www.cnbc.com/2025/08/07/eli-lilly-lly-q2-2025-earnings-report.html)Conclusion
Eli Lilly’s Q2 2025 results highlight its GLP-1 market dominance, but orforglipron’s setback underscores pipeline risks. Raised guidance and manufacturing investments signal confidence, but competitive and tariff risks require monitoring.
Disclaimer: This is not financial advice. Investing involves risks, and past performance is not indicative of future results. Always consult a financial advisor and conduct thorough research before making investment decisions.
